ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
ARROWHEAD PHARMACEUTICALS, INC.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$57.23+1.33 (+2.38%)
Close on Oct 19, 2026
- Market cap
- $8.21B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
11.9%+117.7 pts over 5 years
Net margin
-0.2%+95.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +23258.2% | +50.5% | +56.6% | +115.6% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -79.4% | -23.9% | -0.5% | |
| Return on assets | -62.8% | -19.4% | -0.1% | |
| Current ratio | 3.53 | 7.92 | 4.86 | |
| Debt to equity | 0.03 | – | – | |
| Net debt to EBITDA | 1.06× | – | – | |
| Interest coverage | – | – | 1.1× | |
| Capex to revenue | 2438.0% | 13.6% | 2.7% | |
| Diluted shares | 61M | 101M | 134M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Arrowhead Pharmaceuticals generated $1.10B from operations and spent $417.22M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.10B
Used
$417.22M
Capital expenditure$417.22M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-0.2%
×Asset turnover0.66×
×Equity multiplier3.88×
=Return on equity, FY2025-0.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -0.2% | 0.66× | 3.88× | -0.5% |
| FY2024 | -16882.4% | 0.00× | 4.17× | -262.5% |
| FY2023 | -85.3% | 0.33× | 2.18× | -61.3% |
| FY2022 | -72.4% | 0.35× | 1.74× | -43.6% |
| FY2021 | -101.9% | 0.22× | 1.42× | -32.4% |
| FY2020 | -96.1% | 0.20× | 1.23× | -23.9% |
| FY2019 | 40.3% | 0.73× | 1.36× | 39.9% |
| FY2018 | -337.3% | 0.15× | 1.22× | -61.5% |
| FY2017 | -109.5% | 0.27× | 1.31× | -38.8% |
| FY2016 | -51614.6% | 0.00× | 1.27× | -79.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$1.63M
- Cash generatingOperating cash flow above zero$179.55M
- Return on assets improvedROA up on the prior year-78.3% → -0.1%
- Earnings backed by cashOperating cash flow above net income$179.55M vs -$1.63M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose6.74 → 4.86
- No dilutionShare count did not rise120M → 134M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.73